rs10501858 - NAP1L1P1 - RPUSD4
Magnitude 4.5 · 1 study on file
Reported associations
-
TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. - Molecular endocrinology (Baltimore, Md.) (2013) · Liu M, Ingle JN, Fridley BL, Buzdar AU, Robson ME, Kubo M, Wang L, Batzler A, Jenkins GD, Pietrzak TL, Carlson EE, Goetz MP, Northfelt DW, Perez EA, Williard CV, Schaid DJ, Nakamura Y, Weinshilboum RM · PubMed 23518928
We performed a discovery genome-wide association study to identify genetic factors associated with variation in plasma estradiol (E2) concentrations using DNA from 772 postmenopausal women with estrogen receptor (ER)-positive breast cancer prior to the initiation of aromatase inhibitor therapy. Association analyses showed that the single nucleotide polymorphisms (SNP) (rs1864729) with the lowest P value (P = 3.49E-08), mapped to chromosome 8 near TSPYL5. We also identified 17 imputed SNPs in or near TSPYL5 with P values < 5E-08, one of which, rs2583506, created a functional estrogen response element. We then used a panel of lymphoblastoid cell lines (LCLs) stably transfected with ERα with known genome-wide SNP genotypes to demonstrate that TSPYL5 expression increased after E2 exposure of
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Bloodwork
-
Estradiol plasma levels Moderate
This variant is associated with elevated circulating estradiol, which increases breast cancer risk.
Baseline testing and periodic monitoring per clinical assessment.
Discuss with your doctor
-
Breast cancer screening strategy Moderate
Genetic predisposition to elevated estradiol increases breast cancer risk, warranting individualized screening approach.
Discuss baseline risk assessment and personalized screening plan.